PinnyPeptide

DNSP-11 vs PE22-28

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

DNSP-11

Cognitive

Eleven-amino-acid peptide derived from the GDNF prodomain — neuroprotective for dopamine neurons.

Peptide B

PE22-28

Cognitive

Fast-acting antidepressant peptide acting via TREK-1 channel inhibition.

Typical vial

5 mg

Typical dose

Variable (research-specific) mcg

Half-life

Short; precise value uncharacterized

FDA status

Not FDA approved.

Typical vial

5 mg

Typical dose

50-200 mcg

Half-life

Hours; precise value species-dependent

FDA status

Not FDA approved.

DNSP-11 effects

  • Dopaminergic neuroprotection in Parkinson's models
  • Increased dopamine production in dopaminergic neurons
  • Improved motor function in 6-OHDA and MPTP models
  • Mechanism distinct from full-length GDNF
  • Investigational for Parkinson's and related disorders

PE22-28 effects

  • Selective TREK-1 potassium channel inhibition
  • Fast-onset antidepressant-like effects in rodent models
  • Increased serotonergic neuron firing in dorsal raphe
  • Enhanced BDNF / TrkB signaling downstream
  • Anti-anxiety effects in some assays

DNSP-11 side effects

  • Essentially uncharacterized in humans
  • Possible local tissue effects with intracerebroventricular delivery
  • Theoretical: off-target effects on non-dopaminergic neurons
  • Injection-site reactions

PE22-28 side effects

  • Essentially uncharacterized in humans
  • Theoretical: TREK-1 inhibition off-target in heart, immune cells
  • Subjective reports of mood activation, occasional anxiety
  • Injection-site reactions
  • Sleep disturbance with late-day dosing

DNSP-11 dosing ranges

Research / Parkinson's models (preclinical)

Variable per protocol · ICV or peripheral routes · Per research design

PE22-28 dosing ranges

Antidepressant research (preclinical)

100-500 mcg/kg · Daily SubQ or IP · Per protocol

Self-experimentation (no clinical guidance)

50-200 mcg · Once or twice daily · 2-4 weeks per cycle

DNSP-11 vs PE22-28 — common questions

What is the difference between DNSP-11 and PE22-28?

DNSP-11: Eleven-amino-acid peptide derived from the GDNF prodomain — neuroprotective for dopamine neurons. Typical dose Variable (research-specific) mcg. PE22-28: Fast-acting antidepressant peptide acting via TREK-1 channel inhibition. Typical dose 50-200 mcg. Both fall under the Cognitive category.

Can you stack DNSP-11 and PE22-28?

Stacking DNSP-11 with PE22-28 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, DNSP-11 or PE22-28?

DNSP-11 is typically dosed: ICV or peripheral routes for Research / Parkinson's models (preclinical). PE22-28 is typically dosed: Daily SubQ or IP for Antidepressant research (preclinical); Once or twice daily for Self-experimentation (no clinical guidance).

Are DNSP-11 and PE22-28 FDA approved?

DNSP-11: Not FDA approved. PE22-28: Not FDA approved.

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free